Immix Biopharma Inc Financials
This page shows Immix Biopharma Inc (IMMX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Immix’s equity-funded development program uses financing to supply liquidity while research spending consumes it.
FY2025 liquidity expansion came from financing cash flow of$107M while operations used$23.9M , so the cash build was not produced internally. Shares outstanding rose from 27.5M in FY2024 to 52.95M in FY2025, reinforcing that equity funding—rather than operating cash generation—was the principal financing mechanism.
With revenue unreported, profitability and gross-margin lenses cannot establish commercialization economics; the more visible pattern is development spending, with R&D of
Near-term liquidity is substantial relative to current obligations: cash of
Financial Health Signals
We are recalculating Immix Biopharma Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Immix Biopharma Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Immix Biopharma Inc reported a net loss of $29.4M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Immix Biopharma Inc's EBITDA was -$29.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.2% from the prior year.
Immix Biopharma Inc reported -$29.4M in net income in fiscal year 2025. This represents a decrease of 36.0% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Immix Biopharma Inc recorded an outflow of $24.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 56.4% from the prior year.
Immix Biopharma Inc held $93.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Immix Biopharma Inc's ROE was -31.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 131.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Immix Biopharma Inc invested $16.3M in research and development in fiscal year 2025. This represents an increase of 44.0% from the prior year.
Immix Biopharma Inc invested $733K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 37.8% from the prior year.
Not reported for fiscal year 2025.
IMMX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $16.3M+44.0% | $11.3M+29.3% | $8.7M+108.2% | $4.2M+3216.1% | $127K-49.0% | $248K |
| SG&A Expenses | N/A | $13.7M+20.3% | $11.4M+53.7% | $7.4M+84.1% | $4.0M+228.3% | $1.2M+495.8% | $206K |
| Operating Income | N/A | -$30.0M-32.1% | -$22.7M-40.5% | -$16.1M-96.4% | -$8.2M-507.9% | -$1.4M-197.9% | -$454K |
| Interest Expense | N/A | N/A | N/A | N/A | $497-99.7% | $180K+76.4% | $102K |
| Income Tax | N/A | $38K-8.1% | $41K+55.4% | $26K+157.3% | $10K+70.8% | $6K-65.7% | $18K |
| Net Income | N/A | -$29.4M-36.0% | -$21.6M-40.1% | -$15.4M-87.4% | -$8.2M+66.2% | -$24.4M-2024.3% | -$1.1M |
| EPS (Diluted) | — | -$0.89 | -$0.76 | -$0.89-50.8% | -$0.59 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IMMX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $104.8M+356.9% | $22.9M+15.2% | $19.9M+33.7% | $14.9M-18.1% | $18.2M+3271.4% | $540K |
| Current Assets | $101.2M+401.2% | $20.2M+2.1% | $19.8M+32.8% | $14.9M-18.1% | $18.2M+3317.0% | $532K |
| Cash & Equivalents | $93.9M+431.2% | $17.7M+1.0% | $17.5M+30.3% | $13.4M-23.8% | $17.6M+4411.7% | $391K |
| Total Liabilities | $11.0M+13.9% | $9.7M+160.5% | $3.7M+112.9% | $1.7M+765.3% | $202K-96.2% | $5.3M |
| Current Liabilities | $10.1M+16.4% | $8.7M+133.4% | $3.7M+192.3% | $1.3M+530.2% | $202K-96.2% | $5.3M |
| Total Equity | $93.8M+607.8% | $13.3M-19.2% | $16.4M+24.7% | $13.2M-26.8% | $18.0M+480.3% | -$4.7M |
| Retained Earnings | -$104.5M-39.2% | -$75.0M-40.5% | -$53.4M-40.6% | -$38.0M-27.7% | -$29.8M-453.9% | -$5.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
IMMX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.5M | -$23.9M-64.0% | -$14.6M-28.3% | -$11.4M-53.5% | -$7.4M-366.1% | -$1.6M-292.7% | -$405K |
| Capital Expenditures | $591K | $733K-37.8% | $1.2M+2160.9% | $52K | N/A | $802 | N/A |
| Free Cash Flow | -$39.1M | -$24.7M-56.4% | -$15.8M-38.1% | -$11.4M | N/A | -$1.6M | N/A |
| Investing Cash Flow | -$9.1M | -$7.2M-512.5% | -$1.2M-2160.9% | -$52K | N/A | -$802 | N/A |
| Financing Cash Flow | $261.5M | $107.4M+573.3% | $15.9M+3.1% | $15.5M+378.4% | $3.2M-82.9% | $18.8M | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $100K | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IMMX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -31.3%+131.8pp | -163.1%-69.1pp | -94.0%-31.5pp | -62.5%+73.0pp | -135.5% | N/A |
| Return on Assets | -28.0%+66.1pp | -94.2%-16.8pp | -77.4%-22.2pp | -55.2%+78.8pp | -134.0%+78.7pp | -212.7% |
| Current Ratio | 10.01+7.7x | 2.33-3.0x | 5.32-6.4x | 11.70-78.3x | 90.01+89.9x | 0.10 |
| Debt-to-Equity | 0.12-0.6x | 0.73+0.5x | 0.23+0.1x | 0.13+0.1x | 0.01 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Immix Biopharma Inc Ranks
Frequently Asked Questions
Is Immix Biopharma Inc profitable?
No, Immix Biopharma Inc (IMMX) reported a net income of -$29.4M in fiscal year 2025.
What is Immix Biopharma Inc's EBITDA?
Immix Biopharma Inc (IMMX) had EBITDA of -$29.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immix Biopharma Inc's return on equity (ROE)?
Immix Biopharma Inc (IMMX) has a return on equity of -31.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immix Biopharma Inc's free cash flow?
Immix Biopharma Inc (IMMX) recorded an outflow of $24.7M in free cash flow during fiscal year 2025. This represents a -56.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immix Biopharma Inc's operating cash flow?
Immix Biopharma Inc (IMMX) recorded an outflow of $23.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immix Biopharma Inc's total assets?
Immix Biopharma Inc (IMMX) had $104.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immix Biopharma Inc's capital expenditures?
Immix Biopharma Inc (IMMX) invested $733K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immix Biopharma Inc spend on research and development?
Immix Biopharma Inc (IMMX) invested $16.3M in research and development during fiscal year 2025.
What is Immix Biopharma Inc's current ratio?
Immix Biopharma Inc (IMMX) had a current ratio of 10.01 as of fiscal year 2025, which is generally considered healthy.
What is Immix Biopharma Inc's debt-to-equity ratio?
Immix Biopharma Inc (IMMX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Immix Biopharma Inc's return on assets (ROA)?
Immix Biopharma Inc (IMMX) had a return on assets of -28.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immix Biopharma Inc's cash runway?
Based on fiscal year 2025 data, Immix Biopharma Inc (IMMX) had $93.9M in cash against an annual operating cash burn of $23.9M. This gives an estimated cash runway of approximately 47 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Immix Biopharma Inc's Piotroski F-Score?
Immix Biopharma Inc (IMMX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immix Biopharma Inc's earnings high quality?
Immix Biopharma Inc (IMMX) reported a net loss of $29.4M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.